Citizens National Bank Trust Department Acquires 11,285 Shares of Abbott Laboratories $ABT

Citizens National Bank Trust Department raised its holdings in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 77.3% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 25,885 shares of the healthcare product maker's stock after purchasing an additional 11,285 shares during the quarter. Citizens National Bank Trust Department's holdings in Abbott Laboratories were worth $2,349,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. J. Stern & Co. LLP lifted its stake in shares of Abbott Laboratories by 12,439.6% during the 4th quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker's stock worth $4,926,279,000 after buying an additional 39,005,451 shares during the last quarter. Norges Bank acquired a new position in Abbott Laboratories in the 4th quarter valued at about $2,938,892,000. Arrowstreet Capital Limited Partnership grew its stake in Abbott Laboratories by 217.0% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 5,522,222 shares of the healthcare product maker's stock valued at $566,967,000 after buying an additional 3,780,402 shares during the last quarter. Assenagon Asset Management S.A. raised its holdings in Abbott Laboratories by 303.0% in the 1st quarter. Assenagon Asset Management S.A. now owns 4,429,571 shares of the healthcare product maker's stock valued at $454,784,000 after acquiring an additional 3,330,368 shares during the period. Finally, Vanguard Group Inc. lifted its position in Abbott Laboratories by 1.4% during the fourth quarter. Vanguard Group Inc. now owns 175,556,716 shares of the healthcare product maker's stock worth $21,995,501,000 after acquiring an additional 2,402,408 shares during the last quarter. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Abbott Laboratories Stock Up 1.6%

Shares of ABT opened at $114.50 on Thursday. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $137.49. The firm's 50 day moving average is $99.02 and its 200-day moving average is $99.90. The stock has a market capitalization of $198.13 billion, a PE ratio of 37.06, a P/E/G ratio of 2.18 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.28 by $0.03. The business had revenue of $12.59 billion during the quarter, compared to analysts' expectations of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The firm's revenue for the quarter was up 13.0% compared to the same quarter last year. During the same period in the previous year, the company posted $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Equities research analysts forecast that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th were given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date was Wednesday, July 15th. Abbott Laboratories's dividend payout ratio is presently 81.55%.

Analyst Upgrades and Downgrades

ABT has been the topic of several research reports. Piper Sandler reaffirmed an "overweight" rating and issued a $118.00 target price (up from $115.00) on shares of Abbott Laboratories in a research report on Friday, July 17th. Wolfe Research raised Abbott Laboratories from a "peer perform" rating to an "outperform" rating and set a $130.00 price target for the company in a report on Thursday, August 13th. Daiwa Securities Group downgraded Abbott Laboratories from an "outperform" rating to a "neutral" rating and set a $92.00 price target for the company. in a research note on Wednesday, April 22nd. Robert W. Baird assumed coverage on Abbott Laboratories in a research report on Wednesday, July 1st. They set an "outperform" rating and a $121.00 price objective on the stock. Finally, BTIG Research lifted their target price on Abbott Laboratories from $131.00 to $134.00 and gave the stock a "buy" rating in a report on Friday, July 17th. Three investment analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, Abbott Laboratories has an average rating of "Moderate Buy" and an average target price of $118.67.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source